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httpcense.Abstract Background: Sleep disordered breathing (SDB) is a prevalent, but forgotten, cardiovas-
cular (CV) risk factor in end-stage renal disease patients. Studies of SDB in renal transplant patients
are few with mixed results.
Objectives: To assess the prevalence and clinical correlates of SA in patients who received a kid-
ney transplant, and to compare the prevalence of SA between waiting list and transplant patients.
Subjects and methods: Our study included 40 clinically stable renal transplant patients and 15
patients awaiting transplantation. Patients with morbid obesity, diabetes, pulmonary disease or
symptomatic heart failure were excluded from the study. All patients underwent overnight polysom-
nography, demographic and clinical data were also collected.
Results: We found that the prevalence of SA was high in both the transplant and the waiting list
groups (38% vs 47%). The severity of SA didn’t show signiﬁcant difference in both groups
(AHI = 9.6 vs 16.2). Moreover, we found a signiﬁcant association between impaired renal function
and the AHI in Tx patients. Also, SA was associated with difﬁcult-to-treat hypertension in Tx
patients as we found a signiﬁcant association between the AHI and the systolic blood pressure as
well as the number of prescribed antihypertensive drugs.
Conclusion: SA is as highly prevalent in Tx as in WL patients. Moreover, this high prevalence in the
transplant patients could be a consequence of declining renal function. In addition, we propose that sleep
apnea is a new risk factor for hypertension and cardiovascular events in kidney-transplanted patients.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.partment of Chest Diseases,
e, Alexandria, Egypt.
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://dx.doi.org/10.1016/j.ejcdt.2012.0IntroductionSleep apnea (SA) is a surprisingly common disorder in end-
stage renal disease (ESRD) and chronic renal failure [1]. Previ-
ous studies have shown high prevalence of SA (16–60%) in pa-
tients with ESRD [2,3]. Although the underlying mechanisms
linking these two conditions remain to be better deﬁned, it is
likely that multiple factors are involved [2].is. Production and hosting by Elsevier B.V.
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454 R. Daabis, E. El-GoharyThe symptoms of sleep apnea frequently go unreported or
may be misdiagnosed as uremia, depression, chronic illness,
or insomnia. Sleep apnea is reportedly associated with higher
risk for stroke, hypertension, diabetes, congestive heart failure,
arrhythmias, metabolic syndrome and also with fatal and non-
fatal cardiovascular events [4].
Although it has been claimed that renal transplantation
may improve the SA in patients with ESRD, consistent infor-
mation about SA in patients who have received a kidney trans-
plant is scarce [5,6].
Among patients who receive kidney transplants, cardiovas-
cular disease is the leading cause of mortality [7]. Since SA may
contribute to the increased cardiovascular risk in transplant
patients we chose to study the prevalence and clinical corre-
lates of SA in these patients.
Aim of the work
The objectives of the study were to assess the prevalence and
clinical correlates of SA in patients who received a kidney
transplant, and to compare the prevalence of SA among wait-
ing list and transplant patients.
Subjects and methods
Patients attending the Transplant Clinic at Alexandria Main Uni-
versity Hospital were invited to participate in the study. Potential
recruits were either patients on hemodialysis for at least 3 months
and awaiting kidney transplantation or post transplant patients.
All transplant patients underwent living donor kidney transplanta-
tion at least 3 months before enrollment. Following transplanta-
tion all patients were taking prednisone and a combination of
two other immunosuppressive drugs and were free of acute
rejection, infectious and acute cardiovascular events.
Both groups of patients were included regardless of sleep com-
plaints. In order to exclude sleep disorders not directly related to
their underlying renal dysfunction, patients with class III obesity
(BMIP40), previous diagnosis of SA, recent start (<3 months)
on dialysis or transplantation, diabetes, pulmonary disease, symp-
tomatic heart failure, hospitalization within 1 month, and surgery
within 3 months, were excluded from the study. Therefore, 40 clin-
ically stable renal transplant patients and 15 patients awaiting
transplantationparticipated in the study.All patientswere enrolled
in the study after a written informed consent according to a proto-
col approved by the Ethics Committee of AlexandriaMain Uni-
versity Hospital (Faculty of Medicine).
Data were collected regarding anthropometric and demo-
graphic factors, medication use, co-morbid conditions, and
laboratory parameters.
Pretransplant patients underwent polysomnography after a
hemodialysis session. All had to have their dry weight assessed
to be included in the study. Prior to polysomnography clinical
examination, weight, height and BMI were assessed for both
groups. Just after polysomnography blood samples were taken
for laboratory parameters.
Assessment of daytime sleepiness
The Epworth Sleepiness Scale (ESS) was used for assessing
daytime sleepiness. This is a commonly used self-administeredscale with eight items about how easily the respondent would
fall asleep in different situations. The items are scored on a 0–
3 scale, which are added to give an overall score of 0–24. Higher
scores indicate more sleepiness. ESS score 2–10 is considered
‘normal’ and >10 indicative of pathological sleepiness [8].
Polysomnography
All patients underwent overnight polysomnography in the
chest department, Faculty of Medicine, Alexandria University,
using RESMED Apnea LinkTM System which measured the
following cardiorespiratory data; respiratory sounds, airﬂow,
oxygen saturation and heart rate [9].
The analysis was carried out automatically and manually.
Respiratory events were scored using standard criteria. The ap-
nea hypopnea index (AHI) was deﬁned as the total number of
apneas and hypopneas per hour of sleep. As indices of nocturnal
hypoxemia we considered the oxygen desaturation index (the
number of O2 desaturation episodes per hour of sleep), T90
(the fraction of sleep time spent below an oxygen saturation of
90 percent), minimal SaO2 (the minimal value recorded during
sleep), and the average oxygen saturation (calculated from the
oxygen saturation values measured during sleep) [10,11].
The presence of SA was deﬁned as an AHI of P5 events/h
and patients were further subdivided into three categories of
severity: mild; AHI P5 and <15, moderate; AHI P15 and
<30, and severe; AHI P30 [10].
Laboratory measurements
Serum urea, creatinine, cholestrol, triglycerides, glucose, albu-
min, and hemoglobin were measured by standard methods in
the routine clinical laboratory. Estimated GFR (eGFR) was
calculated using the Cockroft and Gault formula: creatinine
clearance (ml/min/1.73m2) = (140-age in years) · weight
(kg) · K/ (serum creatinine · 72) [12].
Transplantation data and immunosuppressive therapy
Transplantation-related information collected included current
medications, transplant and dialysis ‘‘vintage’’ (i.e., time elapsed
since transplantation or since the initiation of dialysis treat-
ment), time spent on dialysis before transplantation. Standard
maintenance immunosuppressive therapy generally consisted
of prednisolone, plus either cyclosporin A microemulsion for-
mulation or tacrolimus, combined with mycophenolate mofetil
or azathioprine.
BP measurement
BP was measured in the clinic three times after 10 min of rest.
The average of the three measurements was tabulated. The
number of antihypertensive medications was also collected.
Statistical analysis
Data were collected, tabulated, then analyzed using SPSS
Ver.13. Qualitative data were presented as numbers and per-
centage. Quantitative data were expressed as means and stan-
dard deviation. The prevalence of SA was compared among
Sleep apnea in kidney transplant patients 455the 2 groups using the Z test of proportion. The severity of SA
among the studied groups was compared using the chi square
test. Demographic, clinical and laboratory data between
groups were compared by the chi square test and the Student’s
t-test when appropriate. The Pearson correlation coefﬁcient (r)
was used to assess the relation between AHI and numerical
variables. A 5% level was chosen as a level of signiﬁcance in
all statistical tests used in the study
Results
Demographic data and baseline characteristics of the sample
Fourty clinically stable renal transplant patients (Tx patients)
and 15 patients awaiting transplantation (WL patients) were
enrolled in the study. Baseline patient characteristics are
shown in Table 1. Demographic, clinical and laboratory vari-
ables did not show any statically signiﬁcant difference between
the Tx and WL groups (Table 1).
All of the Tx patients were taking steroids, 75% were
administered cyclosporin A, 65% were on mycophenolate
mofetil, 25% patients were administered tacrolimus, and
35% were on azathioprine.
Prevalence and severity of SA in Tx versus WL dialysis patients
Fifteen patients (38%) of the Tx and seven patients (47%) of
WL patients had SA (AHIP5; showing no statistically signif-
icant difference) (Table 2). The respiratory sleep parameters
did not show signiﬁcant differences between the two studied
groups as shown in Table 2. There was no signiﬁcant difference
in the severity of SA among the two studied groups, where the
prevalence of mild, moderate, and severe SA in the Tx and WL
groups were: 23%, 10%, and 5% in the Tx group and 13%,
27%, and 7% in the WL group, respectively (Fig. 1).Table 1 Patient characteristics.
Characteristic Tx Patients
Male (n, %) 27 (68)
Age (yr) 39 ± 8.29
Tobacco use (n, %) 11 (28)
BMI (kg/m2) 28 ± 3
Prevalence of hypertension (n, %) 36 (90)
Number of antihypertensive drugs used (n, %)
1 2 (5)
2 24 (60)
P3 10 (25)
Hb (g/dl) 11.9 ± 1.12
Systolic pressure (mmHg) 140 + 14.14
Diastolic pressure (mmHg) 78 ± 11.55
Serum albumin (g/dl) 3.5 ± 0.4
Serum cholesterol(mg/dl) 211.5 ± 44.7
Serum triglycerides(mg/dl) 143.25 ± 43
Serum urea(mg/dl) 29 ± 9.77
Serum creatinine(mg,dl) 1.65 ± 0.79
eGFR(ml/min/1.73m2) 58.3 ± 30.16
Transplant or dialysis vintage (months) 56 ± 37.7
Results are expressed as mean + standard deviation unless otherwise spe
mass, HB: hemoglobin, eGFR: estimated glomerular ﬁltration rate.Correlates of SA in the Tx group
The AHI was signiﬁcantly correlated with the eGFR
(p= 0.040), systolic blood pressure (p= 0.003), as well as
the number of prescribed antihypertensive drugs (p= 0014)
(Table 3). Otherwise, the AHI did not show any signiﬁcant
correlation with other demographic, clinical or laboratory
data.
Discussion
In this study we aimed to assess the prevalence of SA in pa-
tients who received a kidney transplant, in comparison to pa-
tients with ESRD who are on the transplant waiting list. We
found that the prevalence of SA was comparably high in the
transplant and the waiting list patients, (38% and 47%, respec-
tively, NS). Moreover, the AHI did not show signiﬁcant differ-
ence between the transplant and the waiting list groups (9.6
and 16.2, respectively) where the severity of SA was the same
in both groups. Previous studies have yielded mixed results;
few patients have been described to have their SA cured with
renal transplant [5,6]. On the other hand, other studies, sug-
gested that SA may not show signiﬁcant improvement after
transplantation. A recent study found that 27% of renal trans-
plant patients had a high likelihood for SA based on the Berlin
questionnaire, this was comparable to the 33% who were on
the transplant waiting list, including dialysis patients [13].
Also, Molnar et al. in a cross-sectional study of 100 Tx and
50 WL patients who underwent one-night polysomnography,
showed that the prevalence of OSA was similarly high in both
groups [7]. Therefore our results adds further evidence that the
post-transplant state also appears to be a risk factor for SA.
The exact pathophysiologic factors linking ESRD and
SAHS remain unclear and controversial, and there may be
multiple independent factors impacting the association.(n= 40) WL Patients (n= 15) P
17 (73) NS
34 ± 5.66 NS
5 (33) NS
24 ± 2 NS
11 (73) NS
1 (7) NS
8 (53)
2 (13)
10.95 ± 1.5 NS
135 + 33.17 NS
80 ± 7.36 NS
3.6 ± 0.6 NS
5 148 ± 32.12 NS
.11 147 ± 38.5 NS
76.5 ± 27.38 P= 0.031
5.15 ± 4.13 NS
NA
14 ± 5.7 NS
ciﬁed. Deﬁnition of abbreviations: n: number of patients, BMI:body
Table 2 Sleepiness and respiratory sleep parameters in Tx and WL patients.
Parameter Tx patients WL patients
Patients with SA n (%) 15 (38) 7 (47) NS
AHI 9.6 ± 7.64 16.2 ± 5.83 NS
ODI 4.3 ± 6.16 4 ± 1,41 NS
Minimum oxygen saturation during sleep (%) 84.3 ± 8.50 75 ± 16.97 NS
Average oxygen saturation during sleep (%) 95 ± 1.73 90.5 ± 4.95 NS
T 90% 5.02 ± 8.65 6.4 ± 4.81 NS
ESS 6.5 ± 0.71 7.8 ± 3.54 NS
Results are expressed as mean + standard deviation. Deﬁnition of abbreviations: AHI: apnea hypopnea index, ODI: oxygen desturation index,
T90: fraction of sleep time spent below an oxygen saturation of 90 percent, ESS: Epworth sleepiness scale.
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Figure 1 Prevalence and severity of OSA in Tx and WL patients.
Table 3 Correlation between AHI and selected variables in
Tx patients.
Parameter AHI
r p
eGFR 0.326 0.040*
Systolic pressure 0.452 0.003*
Number of antihypertensive drugs 0.387 0.014*
nP: p value for pearson correlation. *: Statistically signiﬁcant at p 6
0.05.
456 R. Daabis, E. El-GoharyVolume overload, a common problem in patients with ESRD,
causes redistribution of body water during the recumbent po-
sition and gives rise to upper airway edema causing pharyngeal
narrowing that predispose to upper airway collapse during
sleep leading to obstructive sleep apnea [14]. Accumulation
of uremic toxins induces metabolic acidosis and hypocapnea
increases chemosensitivity to carbon dioxide leading predomi-
nantly to central sleep apnea [15]. Uremia has also been theo-
rized to contribute to SAHS through uremic-related myopathy
and neuropathy. Myopathy related to uremia can involve the
muscles of the respiratory system and thus predispose to upper
airway collapse during sleep [16]. Peripheral and autonomic
neuropathies, by affecting the innervation of the pharyngeal
dilators, could also lead to upper airway collapse during sleep.
However, unlike uremic myopathy, uremic neuropathy is
generally irreversible and sleep apnea would thus persist post-transplantation [17]. Other factors pertinent to patients with
ESRD may affect the control of ventilation during sleep, as
shown in animal studies, severe anemia enhances hypoxia-in-
duced ventilatory responses and could thus predispose to peri-
odic breathing [6]. Finally, cytokines could have a role in both
ESRD and SA. Tumor necrosis factor-alpha (TNF-a), a cyto-
kine that is elevated in individuals with chronic renal failure
[18], might have a role in the underlying pathophysiologic
course of SAHS, as a study found TNF-a levels abnormally
elevated in patients with SAHS compared with controls [19].
Several of these underlying factors for SA in ESRD persist
after kidney transplantation, and therefore should be consid-
ered as possible contributors for the high prevalence of SA
in Tx patients [20].
Moreover, we found a signiﬁcant association between im-
paired renal function in Tx patients and the AHI. It is possible,
that the surprisingly high prevalence of SA observed in the Tx
population is the consequence of declining renal function in
these patients. This result lends further support to the hypoth-
esis that uremia-related factors may be involved in the patho-
genesis of ESRD-associated SA [21].
On the other hand, other factors typically associated with
sleep disordered breathing (SDB) appear following kidney
transplantation. SDB have been described as being related to
cushing disease and to corticosteroid effect [22], so the contribu-
tion of immunosuppressive therapy to the high prevalence of SA
in the Tx patients in our study cannot be excluded. Since recent
weight gain is common in patients with newly diagnosed SDB
[23], therefore weight gain that occurs following transplantation
could be another confounding factor for the increased risk for
new-onset OSA. Although, we didn’t ﬁnd a signiﬁcant correla-
tion between the AHI and the BMI in our studied Tx patients,
the effect of this risk factor cannot be excluded. Therefore, the
post transplant state due tomultiple factors such as medications
along with improved nutrition and appetite may represent an-
other risk factor for SA [24]. Finally, extracellular water may in-
crease in at least some of the Tx patients [25,26], which may also
be associated with increased risk for OSA [27].
In the general population, SA is associated with male gen-
der [28] and older age [29]. These relationships are less evident
in ESRD related SA and posttransplantation, ﬁndings from
previous studies have been controversial [7,21,30–32]. In our
study, the majority of our patients were young, which could
be contributing factors to our lack of demonstrating similar
associations. And since, SDB is also associated with diabetes,
[33] pulmonary diseases [34] and heart failure [35], therefore
we excluded patients with these comorbidites to avoid con-
founding factors that could cause SA.
Sleep apnea in kidney transplant patients 457In our study, SA was associated with difﬁcult-to-treat
hypertension in Tx patients as we found a signiﬁcant associa-
tion between the AHI and the systolic blood pressure as well
as the number of prescribed antihypertensive drugs. The asso-
ciation of OSA and hypertension is well documented in other
patient populations [36,37]. This result has important clinical
implications, as hypertension is an independent risk factor
for allograft dysfunction [38,39] and cardiovascular mortality
[40] in kidney transplant recipients. Therefore, we propose that
the higher BP in Tx patients with SA may contribute to the
high cardiovascular morbidity and mortality of Tx patients.
Cardiovascular disease remains the leading cause of mortal-
ity in this patient population [40]. Recent ﬁndings suggest that
sleep apnea is associated with increased mortality in dialysis-
dependent patients [41]. Obstructive sleep apnea which persists
following transplantation may therefore contribute to the
increased risk of cardiovascular disease and reduced life expec-
tancy among kidney transplant recipients [42,43]. Our ﬁndings
highlight the potential clinical consequences of persistent
sleep apnea in this patient population and the need for com-
prehensive re-evaluation of sleep apnea following kidney
transplantation.
From our study we conclude that SA is as highly prevalent
in Tx as in WL patients. Moreover, this high prevalence in the
transplant patients could be a consequence of declining renal
function. In addition, we propose that sleep apnea is a new risk
factor for hypertension and cardiovascular events in kidney-
transplanted patients. And since, recognition and treatment
of sleep-related breathing disorders has the potential to both
improve the quality of life and decrease morbidity and mortal-
ity in this patient population [44]. Therefore, we suggest that
screening for SA should be routinely performed, and appropri-
ate treatment should be offered for Tx patients.
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